More than two billion people around the world still do not have access to medicines, with low- and middle-income countries (LMICs) often facing the highest burden of disease. At Takeda, we’re committed to broadening sustainable access to our innovative medicines in LMICs and in countries with evolving healthcare systems. We do this by working collaboratively to strengthen local healthcare systems and by addressing barriers to access at each stage of the patient journey.
Our 2022 Progress Report articulates our approach to access to medicines and highlights key initiatives aimed at broadening access in LMICs by building sustainable capacity, creating innovative affordability programs and collaborating with policymakers to drive meaningful change.
As a patient-focused, values-based, R&D-driven global biopharmaceutical company, Takeda is committed to discovering and delivering life-transforming medicines and vaccines to patients regardless of where they live or what they can afford to pay. We're committed to broadening our end-to-end access work to address barriers to access treatment.
We adapt international know-how to meet the unique needs of local healthcare systems, working to understand and address healthcare infrastructure and capacity across the entire patient journey.
We mobilize collective efforts within and outside our organization to make a meaningful difference to the lives of patients and their local communities. Here is a story of a patient supported by our Access to Medicines programs in the Philippines.
Our signature Blueprint for Innovative Healthcare Access mobilizes collective action to address access barriers and enhance local care for patients living with non-communicable diseases in LMICs.